Attorney Jessie Paluch, founder of TruLaw, has over 25 years of experience as a personal injury and mass tort attorney, and previously worked as an international tax attorney at Deloitte. Jessie collaborates with attorneys nationwide — enabling her to share reliable, up-to-date legal information with our readers.
This article has been written and reviewed for legal accuracy and clarity by the team of writers and legal experts at TruLaw and is as accurate as possible. This content should not be taken as legal advice from an attorney. If you would like to learn more about our owner and experienced injury lawyer, Jessie Paluch, you can do so here.
TruLaw does everything possible to make sure the information in this article is up to date and accurate. If you need specific legal advice about your case, contact us by using the chat on the bottom of this page. This article should not be taken as advice from an attorney.
The FDA is alerting consumers that there is an Invokana amputation risk associated with the popular diabetes drug.
The FDA is now requiring a black box warning on the label so that consumers are aware of the foot and leg amputation risk.
Following the FDA-mandated CANVAS trial (1), which found that Invokana doubled the risk of lower limb amputations compared with patients taking a placebo, many healthcare providers have decided to stop prescribing the diabetes drug.
The CANVA trials started in 2009.
Initially, the trials showed beneficial results that prompted the FDA to approve Invokana in 2013.
But, recent studies show that Invokana side effects include more than amputation.
They also include the life-altering side effects of kidney damage and diabetic ketoacidosis.
According to the Canva study, half of the amputations observed were of toes, while the remainder included the foot, above the ankle, below the knee and above the knee.
Because Invokana is prescribed to people with Type-2 diabetes, patients are already at a higher risk for amputation.
The study showed that patients that have already undergone amputation are at a much higher risk of secondary amputation if they are taking Invokana
In mid-May, following the CANVA results, the FDA ordered Invokana to carry a new black-box label warning patients of the increased risks of lower limb amputations.
The warning urged patients using Invokana to contact their doctor “right away” if they experience any pain or tenderness, sores, ulcers, or infections in their legs or feet.
Though the author of the CANVA study says that the drug does show success in reducing the risk of cardiovascular events, the newly associated risks of amputation has led healthcare providers to take preemptive measures to avoid future amputation lawsuits brought upon by patients affected by Invokana.
To avoid the threat of amputation lawsuits, doctors have begun to use alternative treatments for Type-2 diabetes patients.
Some healthcare providers have also started to substitute prescriptions for current Invokana users.
The focus is mostly on patients with predisposed conditions that put them at a higher risk of amputation, such as patients who have previously undergone amputation.
While a number healthcare systems have now taken Invokana off of their list of drug treatments for hospitalized patients, the popularity of the drug still puts many Type-2 diabetes patients at risk.
TruLaw urges all patients on Invokana to speak to a healthcare provider about the Invokana amputation risk.
Please do not stop taking any medications until you have spoken to your physician or healthcare provider.
It is estimated that 4.5 million Invokana prescriptions were filled in 2016 in the United States, alone.
However, it is expected that the FDA’s black box warning will cause a huge decrease in sales of Invokana as the number of prescriptions will decrease significantly as it will likely alarm patients.
There is no indication that manufacturer Janssen — a subsidiary of Johnson & Johnson pharmaceutical — plans on taking the current form of Invokana off the market.
Invokana lawsuits are currently being filed on behalf of individuals who were injured while taking Invokana.
Experienced Attorney & Legal SaaS CEO
With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three. She spent the first decade of her career working as an international tax attorney at Deloitte.
In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.
In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TruLaw, we fiercely combat corporations that endanger individuals’ well-being. If you’ve suffered injuries and believe these well-funded entities should be held accountable, we’re here for you.
With TruLaw, you gain access to successful and seasoned lawyers who maximize your chances of success. Our lawyers invest in you—they do not receive a dime until your lawsuit reaches a successful resolution!
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
AFFF Lawsuit claims are being filed against manufacturers of aqueous film-forming foam (AFFF), commonly used in firefighting.
Claims allege that companies such as 3M, DuPont, and Tyco Fire Products failed to adequately warn users about the potential dangers of AFFF exposure — including increased risks of various cancers and diseases.
Suboxone Tooth Decay Lawsuit claims are being filed against Indivior, the manufacturer of Suboxone, a medication used to treat opioid addiction.
Claims allege that Indivior failed to adequately warn users about the potential dangers of severe tooth decay and dental injuries associated with Suboxone’s sublingual film version.
Social Media Harm Lawsuits are being filed against social media companies for allegedly causing mental health issues in children and teens.
Claims allege that companies like Meta, Google, ByteDance, and Snap designed addictive platforms that led to anxiety, depression, and other mental health issues without adequately warning users or parents.
Transvaginal Mesh Lawsuits are being filed against manufacturers of transvaginal mesh products used to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI).
Claims allege that companies like Ethicon, C.R. Bard, and Boston Scientific failed to adequately warn about potential dangers — including erosion, pain, and infection.
Bair Hugger Warming Blanket Lawsuits involve claims against 3M — alleging their surgical warming blankets caused severe infections and complications (particularly in hip and knee replacement surgeries).
Plaintiffs claim 3M failed to warn about potential risks — despite knowing about increased risk of deep joint infections since 2011.
Baby Formula NEC Lawsuit claims are being filed against manufacturers of cow’s milk-based baby formula products.
Claims allege that companies like Abbott Laboratories (Similac) and Mead Johnson & Company (Enfamil) failed to warn about the increased risk of necrotizing enterocolitis (NEC) in premature infants.
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?